September 6, 2023 02:25 PM EDT
R&D
Pharma

Janssen looks to turn PhI­II win for Ry­bre­vant in EGFR-mu­tat­ed NSCLC in­to pres­sure on As­traZeneca block­buster

Zachary Brennan

Senior Editor

John­son & John­son’s Janssen said Wednes­day that its bis­pe­cif­ic an­ti­body Ry­bre­vant (ami­van­tam­ab-vmjw) in com­bo with laz­er­tinib met its dual pri­ma­ry end­points …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times